A CNBC reporter since 1990, Bob Pisani has reported on Wall Street and the stock market from the floor of the New York Stock Exchange for more than a decade. Pisani covered the real estate market for CNBC from 1990-1995, then moved on to cover corporate management issues before moving to the New York Stock Exchange in 1997.
He was nominated twice for a "CableACE Award"—in 1993 and 1995.
In 2013, he won Third Place in the National Headliner Awards in the Business and Consumer Reporting category for his documentary on the diamond business, "The Diamond Rush."
In 2014, Bob was honored with a Recognition Award from the Market Technicians Association for "steadfast efforts to integrate technical analysis into financial decision making, journalism and reporting."
Prior to joining CNBC, Pisani co-authored "Investing in Land: How to Be a Successful Developer." He and his father taught a course in real estate development at the Wharton School of Business at the University of Pennsylvania from 1987-1992. Pisani learned the real estate business from his father, Ralph Pisani, a retired real estate developer.
Follow Bob Pisani on Twitter @BobPisani.
Biotech, which has been a market leader all year, is weak, with both the market-cap weighted IBB and equal weighted XBI down roughly 4 percent each.
The big question ahead of the Federal Reserve meeting this week is how the central bank will characterize the economy.
Competition alive and well in equity space.
Despite earnings, investors cannot help but notice the continuing impact of the strong dollar on tech revenues.
Three former U.S. Treasury Secretaries agree: The U.S. has plenty of problems, but it's still in a dominant position.
Gold surged amid market intrigue surrounding a deal between Venezuela and Citi to swap cash for part of the country's gold reserves.
It might soon be time to hand your money to the robots.